Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | PGK1 | P00558 | 1/20 | 0.59 |
| ▸ | PGK2 | P07205 | 1/20 | 0.59 |
| ▸ | NT5E | P21589 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioguanosine SCHEMBL3861782 | 0.94 | CYP2C19 (0.67) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL3294897 | 0.94 | CYP2C19 (0.67) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL8185769 | 0.91 | CYP2C19 (0.73) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL4083505 | 0.91 | CYP2C19 (0.73) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL608145 | 0.91 | CYP2C19 (0.73) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL23927999 | 0.91 | CYP2C19 (0.73) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL6748957 | 0.91 | CYP2C19 (0.73) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL8612570 | 0.90 | CYP2C19 (0.72) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL8612560 | 0.90 | CYP2C19 (0.72) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| 6-Thioguanylic Acid SCHEMBL15833214 | 0.88 | CA5A (0.69) | ADORA1NT5EP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524851-B2 | Diagnostic methods for therapeutic compounds and methods for monitoring azathioprine therapy | ROBERT BOSCH GESELLSCHAFT FUR MEDIZINISCHE FORSCHUNG (RBMF) (DE) | 2009-04-28 | — | — | US | claimed |
| EP-4720100-A1 | MODIFIED VECTORS | CSL Behring LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250354166-A1 | LENTIVIRAL VECTORS USEFUL FOR THE TREATMENT OF DISEASE | CSL BEHRING L L C (US) | 2025-11-20 | — | — | US | disclosed |
| EP-3655534-B1 | COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES | CSL BEHRING GENE THERAPY INC (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250213580-A1 | Improved Thiopurine Formulation and Treatment Methods | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2025-07-03 | — | — | US | disclosed |
| CN-120193018-A | Method for modifying the specificity of non-coding RNA molecules for silencing gene expression in eukaryotic cells | 热带生物科学英国有限公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4499105-A1 | IMPROVED THIOPURINE FORMULATION AND TREATMENT METHODS | Douglas Pharmaceuticals Limited (NZ) | 2025-02-05 | — | — | EP | disclosed |
| CN-111448318-B | Method for modifying the specificity of non-coding RNA molecules for silencing gene expression in eukaryotic cells | 热带生物科学英国有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240423989-A1 | NOVEL FORMULATION AND TREATMENT METHODS | ProdrugXtend Pty Ltd (AU) | 2024-12-26 | — | — | US | disclosed |
| WO-2024241281-A1 | MODIFIED VECTORS | CSL BEHRING L.L.C. (US) | 2024-11-28 | — | — | WO | disclosed |
| EP-3655534-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES | Calimmune, Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3541392-A1 | IN VIVO CHEMOSELECTION WITH LOW DOSE THIOGUANINE | Calimmune Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190269687-A1 | In Vivo Chemoselection with Low Dose Thioguanine | CALIMMUNE INC (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190256855-A9 | COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES | CALIMMUNE INC (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190100759-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES | CALIMMUNE INC (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2019058253-A1 | MODIFYING THE SPECIFICITY OF NON-CODING RNA MOLECULES FOR SILENCING GENE EXPRESSION IN EUKARYOTIC CELLS | Tropic Biosciences UK Limited (GB) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019018383-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES | Calimmune, Inc. (US) | 2019-01-24 | — | — | WO | disclosed |
| US-20180235972-A1 | NOVEL FORMULATION AND TREATMENT METHODS | ProdrugXtend Pty Ltd (AU) | 2018-08-23 | — | — | US | disclosed |
| WO-2018094126-A1 | IN VIVO CHEMOSELECTION WITH LOW DOSE THIOGUANINE | Calimmune, Inc. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180140606-A1 | In Vivo Chemoselection with Low Dose Thioguanine | CALIMMUNE INC (US) | 2018-05-24 | — | — | US | disclosed |